Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin II versus noradrenaline for vasodilatory shock
ACTRN12621001043820Phase 2Recruiting
- Sponsor
- Austin Health
- Start
- Oct 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Vasoplegia comparing Angiotensin II with Noradrenaline (2 arms). Primary endpoint: Serum creatinine. Started Oct 2021; status: recruiting.
02
Drugs
Angiotensin IInorepinephrine
03
Conditions
Vasoplegia
Beyond the preview
Go deeper on ACTRN12621001043820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001043820.